Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
نویسندگان
چکیده
منابع مشابه
Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
OBJECTIVE To evaluate cost-utility of infliximab and adalimumab for the treatment of moderate-to-severe ulcerative colitis (UC) refractory to conventional therapies in Canada. METHODS A Markov model was constructed to evaluate incremental cost-utility ratios (ICUR) of 5 mg/kg and 10 mg/kg infliximab and adalimumab therapies compared to 'usual care' in treating a hypothetical cohort of patient...
متن کاملEconomic Evaluation of Infliximab for Treatment of Refractory Ulcerative Colitis in Iran: Cost-Effectiveness Analysis
The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. Hypothetical patients, were individuals with moderate to sev...
متن کاملeconomic evaluation of infliximab for treatment of refractory ulcerative colitis in iran: cost-effectiveness analysis
the aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe ulcerative colitis (uc) in iran. we developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. hypothetical patients, were individuals with moderate to sev...
متن کاملEconomic Evaluation of Infliximab for Treatment of Refractory Ulcerative Colitis In Iran: Cost-Effectiveness Analysis.
The aim of this study is to assess cost-effectiveness of infliximab, compared with conventional treatments in patients with moderate to severe Ulcerative Colitis (UC) in Iran. We developed an analytical decision model with a 5-year-time horizon to follow up 1000 hypothetical patients, in order to estimate treatment costs and outcomes. Hypothetical patients were individuals with moderate to seve...
متن کاملLong-term outcome after infliximab for refractory ulcerative colitis.
BACKGROUND AND AIMS Infliximab (IFX) has been shown efficacious for moderate-to-severe ulcerative colitis (UC), but data on long-term efficacy are lacking. We investigated long-term outcome including colectomy rates in outpatients treated with IFX for refractory UC in a single referral centre, and evaluated if predictors could be identified. METHODS The first 121 outpatients (median age 38.0 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cost Effectiveness and Resource Allocation
سال: 2009
ISSN: 1478-7547
DOI: 10.1186/1478-7547-7-20